Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Grows By 18.1%

MiNK Therapeutics, Inc. (NASDAQ:INKT) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 37,106 shares, a growth of 18.1% from the February 12th total of 31,417 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average trading volume of 4,313 shares, the short-interest ratio is presently 8.6 days. Based on an average trading volume of 4,313 shares, the short-interest ratio is presently 8.6 days. Approximately 1.0% of the company’s stock are short sold.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. 2.87% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock traded up $0.45 on Tuesday, reaching $9.57. The company’s stock had a trading volume of 78,963 shares, compared to its average volume of 836,863. The business’s fifty day moving average price is $11.43 and its 200 day moving average price is $12.59. The company has a market cap of $44.88 million, a price-to-earnings ratio of -3.16 and a beta of 0.35. MiNK Therapeutics has a twelve month low of $6.34 and a twelve month high of $76.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.